Argenx on track to add SC efgartigimod to IV option

Dutch autoimmune diseases specialist Argenx (Euronext & Nasdaq: ARGX) has announced positive top-line data from the Phase III ADAPT-SC study evaluating subcutaneous (SC) efgartigimod (1,000mg efgartigimod-PH20) to treat generalized myasthenia gravis (gMG).

SC efgartigimod achieved the primary endpoint of total IgG reduction from baseline at day 29, demonstrating statistical noninferiority to Vyvgart (efgartigimod alfa-fcab) intravenous (IV) formulation in gMG patients.

The IV version of Vyvgart was approved by the US Food and Drug Administration (FDA) in December of 2021.